Cargando…

Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a strong risk factor for liver fibrosis in non-alcoholic fatty liver disease (NAFLD). It remains uncertain why T2DM increases the risk of liver fibrosis. It has been suggested that growth differentiation factor-15 (GDF-15) concentrations increase the ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilson, Josh, Scorletti, Eleonora, Bindels, Laure B., Afolabi, Paul R., Targher, Giovanni, Calder, Philip C., Sethi, Jaswinder K., Byrne, Christopher D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523689/ https://www.ncbi.nlm.nih.gov/pubmed/34663793 http://dx.doi.org/10.1038/s41387-021-00170-3

Ejemplares similares

Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis
por: Clough, Geraldine F., et al.
Publicado: (2020)

Heterogeneity of white adipocytes in metabolic disease
por: Bilson, Josh, et al.
Publicado: (2023)

Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
por: Ballestri, Stefano, et al.
Publicado: (2021)

NAFLD: Is There Anything New under the Sun?
por: Lonardo, Amedeo, et al.
Publicado: (2017)

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
por: Reinson, Tina, et al.
Publicado: (2023)

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Erratum: Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Non-invasive fibrosis assessment in non-alcoholic fatty liver disease
por: Rios, Rafael S., et al.
Publicado: (2020)

Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity
por: Galuppo, Brittany, et al.
Publicado: (2022)

NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
por: Lonardo, Amedeo, et al.
Publicado: (2019)

Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD
por: Sanchez, Jessica I., et al.
Publicado: (2023)

Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
por: Lonardo, Amedeo, et al.
Publicado: (2016)

Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
por: Perez-Diaz-del-Campo, Nuria, et al.
Publicado: (2023)

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
por: Liebig, Stephanie, et al.
Publicado: (2019)

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
por: Cichoż-Lach, Halina, et al.
Publicado: (2012)

The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease
por: Nobili, Valerio, et al.
Publicado: (2009)

A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones
por: Chou, Yu-Tsung, et al.
Publicado: (2021)

The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients
por: Neagoe, Carmen-Daniela, et al.
Publicado: (2020)

TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population
por: Martínez-Escudé, Alba, et al.
Publicado: (2021)

Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
por: Bernstein, David, et al.
Publicado: (2022)

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
por: Vieira Barbosa, Joana, et al.
Publicado: (2021)

Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD
por: Busca, C., et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
por: Tapper, Elliot B., et al.
Publicado: (2016)

Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores
por: Yao, Renling, et al.
Publicado: (2021)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
por: Targher, Giovanni
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease
por: Alkhouri, Naim, et al.
Publicado: (2014)

Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD
por: Wang, Junling, et al.
Publicado: (2016)

TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice
por: Wandrer, Franziska, et al.
Publicado: (2020)

Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
por: Carrieri, Patrizia, et al.
Publicado: (2022)

Growth differentiation factor 15: an emerging diagnostic biomarker of liver fibrosis in chronic hepatitis C patients
por: Abou Zaghla, Heba M. Adel, et al.
Publicado: (2021)

The Immunometabolic Roles of Various Fatty Acids in Macrophages and Lymphocytes
por: Rosa Neto, Jose Cesar, et al.
Publicado: (2021)

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
por: Pearce, Steven G, et al.
Publicado: (2013)

Novel Algorithm for Non-Invasive Assessment of Fibrosis in NAFLD
por: Sowa, Jan-Peter, et al.
Publicado: (2013)

Is melatonin associated with pro-inflammatory cytokine activity and liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients?
por: Sohrabi, Masoudreza, et al.
Publicado: (2021)

Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients
por: Bischoff, Monika, et al.
Publicado: (2022)

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
por: Miao, Lei, et al.
Publicado: (2022)

Telomeres, NAFLD and Chronic Liver Disease
por: Donati, Benedetta, et al.
Publicado: (2016)

Inflammation: The Straw That Broke the NAFLD Liver!
por: Raeman, Reben
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84d0pglai87l7778g1bo5luiqg